– Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to…
Primary endpoint met in phase 2a POC trial in postpartum depression with a MADRS reduction from baseline of –35.4 points (p<0.0001,…
Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase…
Partnership seeks to improve patient outcomes and experience through novel digital and diagnostic solutions.Investment aligns with Danaher's mission to accelerate…
After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX's Board CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ --…
HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing…
VANCOUVER, BC / ACCESSWIRE / January 9, 2025 / Onco-Innovations Limited (CSE:ONCO)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased…
Vivalink honored for enabling technology leadership with its innovative remote patient monitoring solutions CAMPBELL, Calif., Jan. 9, 2025 /PRNewswire/ --…
SALT LAKE CITY, Jan. 9, 2025 /PRNewswire/ -- Survivor Healthcare, a specialty provider of primary supportive care for cancer patients, has…
Dr Jose-Carlos Gutiérrez-Ramos is the Chief Science Officer at Danaher Corporation. He has held senior drug discovery roles at Pfizer,…